These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Sex and gender in pulmonary arterial hypertension. Cheron C; McBride SA; Antigny F; Girerd B; Chouchana M; Chaumais MC; Jaïs X; Bertoletti L; Sitbon O; Weatherald J; Humbert M; Montani D Eur Respir Rev; 2021 Dec; 30(162):. PubMed ID: 34750113 [TBL] [Abstract][Full Text] [Related]
27. Haemodynamic effects of PAH-targeted therapies in pulmonary hypertension due to lung disease: A systematic review and meta-analysis. Farmakis IT; Vazakidis P; Doundoulakis I; Arvanitaki A; Zafeiropoulos S; Boutou A; Karvounis H; Giannakoulas G Pulm Pharmacol Ther; 2021 Jun; 68():102036. PubMed ID: 33979684 [TBL] [Abstract][Full Text] [Related]
28. Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial Hypertension. Condon DF; Agarwal S; Chakraborty A; Auer N; Vazquez R; Patel H; Zamanian RT; de Jesus Perez VA Chest; 2022 Apr; 161(4):1060-1072. PubMed ID: 34655569 [TBL] [Abstract][Full Text] [Related]
29. [Risk stratification methods and their significance in pulmonary arterial hypertension]. Avdeev SN; Tsareva NA Ter Arkh; 2019 Sep; 91(9):150-157. PubMed ID: 32598827 [TBL] [Abstract][Full Text] [Related]
30. New and Emerging Therapies for Pulmonary Arterial Hypertension. Spiekerkoetter E; Kawut SM; de Jesus Perez VA Annu Rev Med; 2019 Jan; 70():45-59. PubMed ID: 30216732 [TBL] [Abstract][Full Text] [Related]
31. Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). Sobanski V; Launay D; Hachulla E; Humbert M Curr Rheumatol Rep; 2016 Feb; 18(2):10. PubMed ID: 26841964 [TBL] [Abstract][Full Text] [Related]
32. Risk assessment tools for survival prognosis: An era of new surrogacy endpoints for clinical outcome measurement in pulmonary arterial hypertension clinical trials? Sanna L; Todea A Respir Med Res; 2022 May; 81():100893. PubMed ID: 35523041 [TBL] [Abstract][Full Text] [Related]
33. The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension. Kanwar M; Raina A; Lohmueller L; Kraisangka J; Benza R Curr Hypertens Rep; 2019 Apr; 21(6):45. PubMed ID: 31025123 [TBL] [Abstract][Full Text] [Related]
34. New Drugs and Therapies in Pulmonary Arterial Hypertension. Shah AJ; Beckmann T; Vorla M; Kalra DK Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982922 [TBL] [Abstract][Full Text] [Related]
35. [Possibilities of Magnetic Resonance Tomography in Diagnosis of Pulmonary Arterial Hypertension]. Shariya AM; Martynyuk TV; Ternovoy SK; Shariya MA Kardiologiia; 2021 Jul; 61(6):97-104. PubMed ID: 34311693 [TBL] [Abstract][Full Text] [Related]
36. The study of risk in pulmonary arterial hypertension. Rubin LJ; Simonneau G; Badesch D; Galiè N; Humbert M; Keogh A; Massaro J; Matucci Cerinic M; Sitbon O; Kymes S Eur Respir Rev; 2012 Sep; 21(125):234-8. PubMed ID: 22941888 [TBL] [Abstract][Full Text] [Related]